Skip to main content

Angiotensin II administration to COVID-19 patients is not advisable


The COVID-19 pandemic is the worst health crisis to afflict the planet in more than 100 years. It is exacerbated by the lack of effective therapies to prevent the disease. In desperation, many therapies are being devised that are totally devoid of scientific credibility which has led to the US Federal Trade Commission (FTC) to issue warning letters to 45 companies making unsupported claims for COVID-19 cures (accessed May 10, 2020). Potentially rational therapies can also be promoted that can arise from misinterpretation or unwarranted extrapolation of preclinical observations [1]. Such therapies have the potential to cause harm to COVID-19 patients. This commentary addresses one such proposed therapeutic approach: administration of angiotensin (Ang) II (Giapreza®) to COVID-19 patients [2]. Hypertension is one of the risk factors associated with the morbidity and mortality of the current COVID-19 pandemic [3], and it is possible that the renin-angiotensin system may exacerbate the severity of COVID-19 [4]. Virtually every medical society promoting cardiovascular health has advised continuing the use of angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) during the COVID-19 pandemic [5], which contraindicates therapeutic administration of Ang II for treatment of COVID-19 patients.

Overlooking the pathological significance of elevated blood pressure that can be caused by Ang II flies in the face of recommendations of the American Heart Association and more specifically, the findings of the SPRINT trial [6]. While the likelihood of hypotensive shock associated with COVID-19 infection is a concern, there is one report of hypotension associated with COVID-19 infections requiring vasopressor therapy [7], and the vasopressors used were primarily norepinephrine and secondarily vasopressin (Pavan Bhatraju, personal communication, April 10, 2020). Moreover, inferences that individuals with hypertension taking angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) are at greater risk of injury from the SARS-CoV-2 virus because of ACE2 upregulation [2, 8, 9] is also disconcerting. There is an increasing body of information affirming the value of ACE inhibitor and ARB treatment not only for protection from adverse cardiovascular events, but also for possible therapeutic benefit against COVID-19 morbidity and mortality [4, 10]. The suggestion that ACE inhibitors and ARBs might increase ACE2 expression in human lungs is unsubstantiated [1]. The animal studies of the relationship between ACE inhibitor and ARB administration and ACE2 expression are ambiguous, limited to mRNA expression studies, or limited to cardiac, kidney, or vascular ACE2, and some report no changes in ACE2, as recently reviewed [5]. There are no human studies showing that binding of Ang II to AT1 receptors increases ACE2 internalization, thereby downregulating ACE2 in the lungs.

It should be noted that Figure 1 of Busse et al. [2] portrays the renin-angiotensin without including angiotensin I or ACE1. Nor is there any representation of Ang-(1-7) the product of ACE2 metabolism of Ang II in the diagram. Angiotensin II is portrayed as a ligand that binds to ACE2 rather than as a substrate that is rapidly metabolized to Ang-(1-7). The AT1 receptor and ACE2 are portrayed as if they were heterodimerized and internalized concurrently, serving as the only means whereby ACE2 is internalized.

Given the similarity between SARS-CoV-1 and SARS-CoV-2, it is not surprising that SARS-CoV-2 downregulates ACE2 [11], as has been shown for SARS-CoV-1, with serious adverse consequences [12]. Thus, any attempts to further downregulate ACE2 with Ang II administration would likely have even more serious adverse consequences.

Inflammation arising from a cytokine storm is one of the major causes of morbidity of SARS-CoV-2 infection, and the ability of Ang II to cause inflammation by activating AT1 receptors is well established [13]. To cite just one of many studies, in a mouse lipopolysaccharide (LPS)-induced acute lung injury (ALI) model, exogenous ACE2 reduced pathological injury to the lung and improved lung function [14]. Two mechanisms were demonstrated for this beneficial effect: metabolic inactivation of Ang II and formation of Ang 1-7. The beneficial effects of ACE2 administration were diminished by an Ang 1-7 antagonist and an AT1 receptor blocker [14].


As noted above [5], the American Heart Association, American College of Cardiology, and many other biomedical societies recommend continuing ACE inhibitor and ARB therapy for hypertension. Thus, the deployment of angiotensin II as a vasopressor would be both unsound in patients on ARB therapy and counter to the established antihypertensive and putative therapeutic effects of ACE inhibitors and ARBs for COVID-19. Of note, as of May 10, 2020, there were 9 trials registered on to assess the therapeutic benefits of ARBs for treating COVID-19 infections, two for Ang 1-7, and none for Ang II.

Availability of data and materials

Supporting data derives from publications cited in the commentary.


  1. 1.

    Sriram K, Insel PA. Risks of ACE inhibitor and ARB usage in COVID-19: evaluating the evidence. Clin Pharmacol Ther. 2020.

  2. 2.

    Busse LW, Chow JH, McCurdy MT, Khanna AK. COVID-19 and the RAAS—a potential role for angiotensin II? Crit Care. 2020;24(1):136.

    Article  Google Scholar 

  3. 3.

    Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020.

  4. 4.

    Zhang P, Zhu L, Cai J, Lei F, Qin JJ, Xie J, Liu YM, Zhao YC, Huang X, Lin L, et al. Association of Inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res. 2020.

  5. 5.

    Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin–angiotensin–aldosterone system inhibitors in patients with Covid-19. N Engl J Med. 2020.

  6. 6.

    Group TSR. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–16.

    Article  Google Scholar 

  7. 7.

    Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, Greninger AL, Pipavath S, Wurfel MM, Evans L, et al. Covid-19 in critically ill patients in the Seattle region - case series. N Engl J Med. 2020.

  8. 8.

    Diaz JH. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. J Travel Med. 2020.

  9. 9.

    Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8(4):e21.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  10. 10.

    Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, Hausvater A, Newman JD, Berger JS, Bangalore S, et al. Renin–angiotensin–aldosterone system inhibitors and risk of Covid-19. N Engl J Med. 2020.

  11. 11.

    Guzzi PH, Mercatelli D, Ceraolo C, Giorgi FM: Master Regulator Analysis of the SARS-CoV-2/Human Interactome. J Clin Med. 2020;9:982.

  12. 12.

    Kochi AN, Tagliari AP, Forleo GB, Fassini GM, Tondo C: Cardiac and arrhythmic complications in Covid-19 patients. J Cardiovasc Electrophysiol 2020. May;31(5):1003–1008. doi:

  13. 13.

    Forrester SJ, Booz GW, Sigmund CD, Coffman TM, Kawai T, Rizzo V, Scalia R, Eguchi S. Angiotensin II signal transduction: an update on mechanisms of physiology and pathophysiology. Physiol Rev. 2018;98(3):1627–738.

    CAS  Article  Google Scholar 

  14. 14.

    Ye R, Liu Z. ACE2 exhibits protective effects against LPS-induced acute lung injury in mice by inhibiting the LPS-TLR4 pathway. Exp Mol Pathol. 2020;113:104350.

    CAS  Article  Google Scholar 

Download references


Kathryn Sandberg reviewed and made editorial suggestions to improve this commentary.


No funding was provided for the preparation of this commentary.

Author information




Robert Speth conceived, researched, and wrote this commentary. The author read and approved the final manuscript.

Corresponding author

Correspondence to Robert C. Speth.

Ethics declarations

Ethics approval and consent to participate

Not applicable

Consent for publication

The author consents to the publication of this manuscript.

Competing interests

The author reports no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Speth, R.C. Angiotensin II administration to COVID-19 patients is not advisable. Crit Care 24, 296 (2020).

Download citation